# Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents

> **NCT02118961** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 446 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis

## Interventions

- **BIOLOGICAL:** Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)
- **BIOLOGICAL:** Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)

## Key facts

- **NCT ID:** NCT02118961
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118961, "Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02118961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*